Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
MLTX
MLTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MLTX News
Imagene Appoints New Chief Medical Officer to Drive Clinical Development
5d ago
Newsfilter
BioTech Surge: MoonLake Rises 30% Following FDA Success
Feb 03 2026
Marketbeat
Avalo Therapeutics Completes Enrollment for AVTX-009 Trial
Feb 02 2026
Benzinga
MoonLake Immunotherapeutics Receives FDA Fast Track Designation for Sonelokimab
Feb 02 2026
seekingalpha
FDA Grants Fast Track Designation to Sonelokimab for PPP Treatment
Feb 02 2026
Newsfilter
TSMC Raises 2026 Capex to $52B-$56B, Boosting Market Confidence
Jan 16 2026
NASDAQ.COM
TSMC Forecasts Strong Q1 Sales and Raises 2026 CapEx to $52B-$56B
Jan 15 2026
NASDAQ.COM
Goldman Sachs Downgrades MoonLake (MLTX) to Sell, Highlights Approval Risks
Jan 15 2026
seekingalpha
TSMC Boosts 2026 CapEx Forecast to $52B-$56B, Reviving AI Demand Confidence
Jan 15 2026
NASDAQ.COM
Goldman Sachs Downgrades MoonLake to Sell, Raises Price Target to $10
Jan 15 2026
Benzinga
MoonLake Immunotherapeutics' Sonelokimab Advances to Phase 3, Stock Surges 54%
Jan 15 2026
stocktwits
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
Jan 09 2026
Benzinga
MoonLake Seeks BLA for Sonelokimab; FDA Confirms Evidence of Effectiveness
Jan 09 2026
Newsfilter
BMO Upgrades Mid-America Apartment Communities to Outperform with $158 Price Target
Jan 09 2026
Benzinga
MoonLake Receives FDA Feedback on SLK Clinical Evidence Strategy for Hidradenitis Suppurativa
Jan 08 2026
Benzinga
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
Jan 08 2026
Benzinga
Show More News
